This inhibits Rhbdf2-TAK1 signaling and downstream JNK/NF-κB phosphorylation, and thus exerting a protective effect against NAFLD, including attenuating IRS1 phosphorylation-mediated insulin resistance and thereby inhibiting glucose production. Here, NFKB1 is linked to metabolic dysfunction-associated steatotic liver disease.